Dee Mangin1,2, Jennifer Lawson3, Jessica Cuppage4, Elizabeth Shaw3, Katalin Ivanyi3,5, Amie Davis3,6, Cathy Risdon3. 1. Department of Family Medicine, McMaster University, Hamilton, Ontario, Canada mangind@mcmaster.ca. 2. University of Otago, Christchurch, New Zealand. 3. Department of Family Medicine, McMaster University, Hamilton, Ontario, Canada. 4. University of Toronto, Ontario, Canada. 5. Stonechurch Family Health Centre, Hamilton, Ontario, Canada. 6. Halton McMaster Family Health Centre, Burlington, Ontario, Canada.
Abstract
PURPOSE: Polypharmacy is a key clinical challenge for primary care. Drugs that should be prescribed for an intermediate term (longer than 3 months, but not indefinitely) that are not appropriately discontinued could contribute to polypharmacy. We named this type of prescribing legacy prescribing. Commonly prescribed drugs with legacy prescribing potential include antidepressants, bisphosphonates, and proton pump inhibitors (PPIs). We evaluated the proportion of legacy prescribing within these drug classes. METHODS: We conducted a population-based retrospective cohort study using prospectively collected data from the McMaster University Sentinel and Information Collaboration (MUSIC) Primary Care Practice Based Research Network, located in Hamilton, Ontario. All adult patients (aged 18 or older) in the MUSIC data set during 2010-2016 were included (N = 50,813). We calculated rates of legacy prescribing of antidepressants (prescription longer than 15 months), bisphosphonates (longer than 5.5 years), and PPIs (longer than 15 months). RESULTS: The proportion of patients having a legacy prescription at some time during the study period was 46% (3,766 of 8,119) for antidepressants, 14% (228 of 1,592) for bisphosphonates, and 45% (2,885 of 6,414) for PPIs. Many of these patients held current prescriptions. The mean duration of prescribing for all legacy prescriptions was significantly longer than that for non-legacy prescriptions (P <.001). Concurrent legacy prescriptions for both antidepressants and PPIs was common, signaling a potential prescribing cascade. CONCLUSIONS: The phenomenon of legacy prescribing appears prevalent. These data demonstrate the potential of legacy prescribing to contribute to unnecessary polypharmacy, providing an opportunity for system-level intervention in primary care with enormous potential benefit for patients.
PURPOSE: Polypharmacy is a key clinical challenge for primary care. Drugs that should be prescribed for an intermediate term (longer than 3 months, but not indefinitely) that are not appropriately discontinued could contribute to polypharmacy. We named this type of prescribing legacy prescribing. Commonly prescribed drugs with legacy prescribing potential include antidepressants, bisphosphonates, and proton pump inhibitors (PPIs). We evaluated the proportion of legacy prescribing within these drug classes. METHODS: We conducted a population-based retrospective cohort study using prospectively collected data from the McMaster University Sentinel and Information Collaboration (MUSIC) Primary Care Practice Based Research Network, located in Hamilton, Ontario. All adult patients (aged 18 or older) in the MUSIC data set during 2010-2016 were included (N = 50,813). We calculated rates of legacy prescribing of antidepressants (prescription longer than 15 months), bisphosphonates (longer than 5.5 years), and PPIs (longer than 15 months). RESULTS: The proportion of patients having a legacy prescription at some time during the study period was 46% (3,766 of 8,119) for antidepressants, 14% (228 of 1,592) for bisphosphonates, and 45% (2,885 of 6,414) for PPIs. Many of these patients held current prescriptions. The mean duration of prescribing for all legacy prescriptions was significantly longer than that for non-legacy prescriptions (P <.001). Concurrent legacy prescriptions for both antidepressants and PPIs was common, signaling a potential prescribing cascade. CONCLUSIONS: The phenomenon of legacy prescribing appears prevalent. These data demonstrate the potential of legacy prescribing to contribute to unnecessary polypharmacy, providing an opportunity for system-level intervention in primary care with enormous potential benefit for patients.
Authors: Wendy Levinson; Marjon Kallewaard; R Sacha Bhatia; Daniel Wolfson; Sam Shortt; Eve A Kerr Journal: BMJ Qual Saf Date: 2014-12-31 Impact factor: 7.035
Authors: Sidney H Kennedy; Raymond W Lam; Roger S McIntyre; S Valérie Tourjman; Venkat Bhat; Pierre Blier; Mehrul Hasnain; Fabrice Jollant; Anthony J Levitt; Glenda M MacQueen; Shane J McInerney; Diane McIntosh; Roumen V Milev; Daniel J Müller; Sagar V Parikh; Norma L Pearson; Arun V Ravindran; Rudolf Uher Journal: Can J Psychiatry Date: 2016-08-02 Impact factor: 4.356
Authors: Silvana Borges; Yeh-Fong Chen; Thomas P Laughren; Robert Temple; Hiren D Patel; Paul A David; Mitchell Mathis; Ellis Unger; Peiling Yang; Ni A Khin Journal: J Clin Psychiatry Date: 2014-03 Impact factor: 4.384
Authors: Taline A Boghossian; Farah Joy Rashid; Wade Thompson; Vivian Welch; Paul Moayyedi; Carlos Rojas-Fernandez; Kevin Pottie; Barbara Farrell Journal: Cochrane Database Syst Rev Date: 2017-03-16
Authors: Laura A Hart; Rod Walker; Elizabeth A Phelan; Zachary A Marcum; Naomi R M Schwartz; Paul K Crane; Eric B Larson; Shelly L Gray Journal: J Am Geriatr Soc Date: 2021-10-19 Impact factor: 5.562
Authors: Ellen Van Leeuwen; Mieke L van Driel; Mark A Horowitz; Tony Kendrick; Maria Donald; An Im De Sutter; Lindsay Robertson; Thierry Christiaens Journal: Cochrane Database Syst Rev Date: 2021-04-15
Authors: M Greiver; S Dahrouge; P O'Brien; D Manca; M T Lussier; J Wang; F Burge; M Grandy; A Singer; M Twohig; R Moineddin; S Kalia; B Aliarzadeh; N Ivers; S Garies; J P Turner; B Farrell Journal: Implement Sci Date: 2019-06-06 Impact factor: 7.327
Authors: Sheny Khera; Marjan Abbasi; Julia Dabravolskaj; Cheryl A Sadowski; Hannah Yua; Bernadette Chevalier Journal: J Prim Care Community Health Date: 2019 Jan-Dec
Authors: Miguel Ángel Hernández-Rodríguez; Ermengol Sempere-Verdú; Caterina Vicens-Caldentey; Francisca González-Rubio; Félix Miguel-García; Vicente Palop-Larrea; Ramón Orueta-Sánchez; Óscar Esteban-Jiménez; Mara Sempere-Manuel; María Pilar Arroyo-Aniés; Buenaventura Fernández-San José; José Ignacio de Juan-Roldán; Ignatios Ioakeim-Skoufa Journal: Int J Environ Res Public Health Date: 2021-04-29 Impact factor: 3.390